XML 204 R122.htm IDEA: XBRL DOCUMENT v3.22.4
Other Consolidated Financial Statement Detail - Other Income (Expense), Net (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Mar. 31, 2022
Feb. 29, 2012
Collaborative arrangements and non-collaborative arrangement transactions            
Gain on sale of equity interest in Samsung Bioepis   $ (1,505.4) $ 0.0 $ 0.0    
Litigation settlement agreement and settlement fees $ 900.0 917.0 0.0 0.0    
Interest income   (89.3) (11.0) (42.0)    
Interest expense   246.6 253.6 222.5    
(Gains) losses on investments, net   277.3 824.9 (685.7)    
Foreign exchange (gains) losses, net   35.5 22.4 10.7    
Other, net   10.1 5.6 (2.9)    
Other (income) expense   $ (108.2) $ 1,095.5 $ (497.4)    
Samsung Bioepis            
Collaborative arrangements and non-collaborative arrangement transactions            
Ownership percentage         49.90% 15.00%